,id,cid,dsn,cmpdname,srccmpd,srccmpdname,srccmpdurl,srctarget,srctargetname,srctargeturl,protacxn,protname,geneid,genename,taxid,taxname,action,actname,actvalue,evids,evurls,pmids,dois,citations
0,1187740,86132,Comparative Toxicogenomics Database (CTD),Cyproconazole,C093628,cyproconazole,https://ctdbase.org/detail.go?type=chem&acc=C093628,1650,DDOST,https://ctdbase.org/detail.go?type=gene&acc=1650,,,1650,DDOST,10090,Mus musculus (house mouse),Cyproconazole results in increased expression of DDOST mRNA,,,PMID:22334560,https://www.ncbi.nlm.nih.gov/pubmed/22334560,22334560,,
1,1187741,86132,Comparative Toxicogenomics Database (CTD),Cyproconazole,C093628,cyproconazole,https://ctdbase.org/detail.go?type=chem&acc=C093628,9879,DDX46,https://ctdbase.org/detail.go?type=gene&acc=9879,,,9879,DDX46,10090,Mus musculus (house mouse),Cyproconazole results in decreased expression of DDX46 mRNA,,,PMID:22334560,https://www.ncbi.nlm.nih.gov/pubmed/22334560,22334560,,
2,1187742,86132,Comparative Toxicogenomics Database (CTD),Cyproconazole,C093628,cyproconazole,https://ctdbase.org/detail.go?type=chem&acc=C093628,1656,DDX6,https://ctdbase.org/detail.go?type=gene&acc=1656,,,1656,DDX6,10090,Mus musculus (house mouse),Cyproconazole results in decreased expression of DDX6 mRNA,,,PMID:22334560|PMID:23970803,https://www.ncbi.nlm.nih.gov/pubmed/22334560|https://www.ncbi.nlm.nih.gov/pubmed/23970803,22334560|23970803,,
3,1187585,104775,Comparative Toxicogenomics Database (CTD),Butyrate,D002087,Butyrates,https://ctdbase.org/detail.go?type=chem&acc=D002087,1636,ACE,https://ctdbase.org/detail.go?type=gene&acc=1636,,,1636,ACE,9606,Homo sapiens (human),[butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased activity of ACE protein mutant form|[butyrates co-treated with bortezomib] results in increased activity of ACE protein mutant form|[butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of ACE protein mutant form,,,PMID:20454656,https://www.ncbi.nlm.nih.gov/pubmed/20454656,20454656,,
4,1187586,222528,Comparative Toxicogenomics Database (CTD),Deoxycholic Acid,D003840,Deoxycholic Acid,https://ctdbase.org/detail.go?type=chem&acc=D003840,2978,GUCA1A,https://ctdbase.org/detail.go?type=gene&acc=2978,,,2978,GUCA1A,9606,Homo sapiens (human),GUCA1A protein results in decreased susceptibility to deoxycholic acid,,,PMID:12507930,https://www.ncbi.nlm.nih.gov/pubmed/12507930,12507930,,
5,1187743,222528,Comparative Toxicogenomics Database (CTD),Deoxycholic Acid,D003840,Deoxycholic Acid,https://ctdbase.org/detail.go?type=chem&acc=D003840,1576,CYP3A4,https://ctdbase.org/detail.go?type=gene&acc=1576,,,1576,CYP3A4,9606,Homo sapiens (human),[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with tartrazine] results in decreased expression of CYP3A4 mrna|[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with acetaminophen] results in decreased expression of CYP3A4 mRNA,,,PMID:33819548,https://www.ncbi.nlm.nih.gov/pubmed/33819548,33819548,,
6,1187744,222528,Comparative Toxicogenomics Database (CTD),Deoxycholic Acid,D003840,Deoxycholic Acid,https://ctdbase.org/detail.go?type=chem&acc=D003840,1577,CYP3A5,https://ctdbase.org/detail.go?type=gene&acc=1577,,,1577,CYP3A5,9606,Homo sapiens (human),[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with atazanavir sulfate] results in decreased expression of CYP3A5 mrna|[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid] results in decreased expression of CYP3A5 mrna|[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with cyclosporine] results in decreased expression of CYP3A5 mrna|[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with acetaminophen] results in decreased expression of CYP3A5 mrna|[glycochenodeoxycholic acid co-treated with deoxycholic acid co-treated with chenodeoxycholic acid co-treated with glycodeoxycholic acid co-treated with glycocholic acid co-treated with tartrazine] results in decreased expression of CYP3A5 mRNA,,,PMID:33819548,https://www.ncbi.nlm.nih.gov/pubmed/33819548,33819548,,
7,1187745,222528,Comparative Toxicogenomics Database (CTD),Deoxycholic Acid,D003840,Deoxycholic Acid,https://ctdbase.org/detail.go?type=chem&acc=D003840,50549,CYP4A1,https://ctdbase.org/detail.go?type=gene&acc=50549,,,50549,Cyp4a1,10116,Rattus norvegicus (Norway rat),Ursodeoxycholic acid inhibits the reaction [deoxycholic acid results in decreased expression of CYP4A1 protein]|deoxycholic acid results in decreased expression of CYP4A1 protein,,,PMID:10453939,https://www.ncbi.nlm.nih.gov/pubmed/10453939,10453939,,
8,1187746,222528,Comparative Toxicogenomics Database (CTD),Deoxycholic Acid,D003840,Deoxycholic Acid,https://ctdbase.org/detail.go?type=chem&acc=D003840,266674,CYP4A8,https://ctdbase.org/detail.go?type=gene&acc=266674,,,266674,Cyp4a8,10116,Rattus norvegicus (Norway rat),[gluconic acid co-treated with deoxycholic acid] results in increased expression of CYP4A8 mRNA,,,PMID:16556975,https://www.ncbi.nlm.nih.gov/pubmed/16556975,16556975,,
